473 related articles for article (PubMed ID: 36186781)
21. Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type.
Vallero SG; Bertero L; Morana G; Sciortino P; Bertin D; Mussano A; Ricci FS; Peretta P; Fagioli F
Front Oncol; 2022; 12():1082062. PubMed ID: 36727064
[TBL] [Abstract][Full Text] [Related]
22. Profile of nimotuzumab in the treatment of high-grade glioma.
Yang QY; Guo CC; Chen ZP
Onco Targets Ther; 2015; 8():819-25. PubMed ID: 25926743
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.
Juratli TA; Qin N; Cahill DP; Filbin MG
Pharmacol Ther; 2018 Feb; 182():70-79. PubMed ID: 28830841
[TBL] [Abstract][Full Text] [Related]
24. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy approaches for the treatment of diffuse midline gliomas.
Bernstock JD; Hoffman SE; Kappel AD; Valdes PA; Essayed W; Klinger NV; Kang KD; Totsch SK; Olsen HE; Schlappi CW; Filipski K; Gessler FA; Baird L; Filbin MG; Hashizume R; Becher OJ; Friedman GK
Oncoimmunology; 2022; 11(1):2124058. PubMed ID: 36185807
[TBL] [Abstract][Full Text] [Related]
26. 2021 updates to the World Health Organization classification of adult-type and pediatric-type diffuse gliomas: a clinical practice review.
Thomas DL
Chin Clin Oncol; 2023 Feb; 12(1):7. PubMed ID: 36922356
[TBL] [Abstract][Full Text] [Related]
27. Treatment Response and Prognosis Evaluation in High-Grade Glioma: An Imaging Review Based on MRI.
Zhou Q; Xue C; Ke X; Zhou J
J Magn Reson Imaging; 2022 Aug; 56(2):325-340. PubMed ID: 35129845
[TBL] [Abstract][Full Text] [Related]
28. Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results.
Picca A; Finocchiaro G
Curr Opin Oncol; 2022 Nov; 34(6):653-660. PubMed ID: 36000367
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic viruses as treatment for adult and pediatric high-grade gliomas: On the way to clinical success.
Hervás-Corpión I; Alonso MM
Int Rev Cell Mol Biol; 2023; 379():169-188. PubMed ID: 37541723
[TBL] [Abstract][Full Text] [Related]
30. Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma.
Petersen CT; Krenciute G
Front Oncol; 2019; 9():69. PubMed ID: 30863720
[TBL] [Abstract][Full Text] [Related]
31. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
32. Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.
Ishikawa E; Yamamoto T; Matsumura A
Neurol Med Chir (Tokyo); 2017 Jul; 57(7):321-330. PubMed ID: 28539528
[TBL] [Abstract][Full Text] [Related]
33. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
34. Paediatric type diffuse high grade gliomas in the WHO CNS5 classification: What the pathologist needs to know?
Rao S; Sahay A; Epari S
Indian J Pathol Microbiol; 2022 May; 65(Supplement):S50-S58. PubMed ID: 35562134
[TBL] [Abstract][Full Text] [Related]
35. T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges.
Haydar D; Ibañez-Vega J; Krenciute G
Front Oncol; 2021; 11():718030. PubMed ID: 34760690
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas.
Noon A; Galban S
Neoplasia; 2023 Jun; 40():100899. PubMed ID: 37030112
[TBL] [Abstract][Full Text] [Related]
37. Treatment advances in high-grade gliomas.
Chen X; Cui Y; Zou L
Front Oncol; 2024; 14():1287725. PubMed ID: 38660136
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
39. Molecular Profiling Reclassifies Adult Astroblastoma into Known and Clinically Distinct Tumor Entities with Frequent Mitogen-Activated Protein Kinase Pathway Alterations.
Boisseau W; Euskirchen P; Mokhtari K; Dehais C; Touat M; Hoang-Xuan K; Sanson M; Capelle L; Nouet A; Karachi C; Bielle F; Guégan J; Marie Y; Martin-Duverneuil N; Taillandier L; Rousseau A; Delattre JY; Idbaih A
Oncologist; 2019 Dec; 24(12):1584-1592. PubMed ID: 31346129
[TBL] [Abstract][Full Text] [Related]
40. Intraoperative 5-ALA fluorescence-guided resection of high-grade glioma leads to greater extent of resection with better outcomes: a systematic review.
Eatz TA; Eichberg DG; Lu VM; Di L; Komotar RJ; Ivan ME
J Neurooncol; 2022 Jan; 156(2):233-256. PubMed ID: 34989964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
